PD-1 (Programmed Cell Death Protein 1) Blockade in Mismatch-repair Deficient Colorectal Cancer in Nigeria
Memorial Sloan Kettering Cancer Center
Summary
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
All subjects Inclusion Criteria: * Age 18 years or older on date of signing informed consent * ECOG performance status of 0 or 1 * Negative pregnancy test done within 72 hours prior to start of treatment for women of childbearing potential. * Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of tislelizumab They must also have a negative urine or serum pregnancy test result ≤ 7 days before first dose of study drug. * The Clinical Trials Facilitation Group recommendations…
Interventions
- DrugTislelizumab
Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
Locations (3)
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Lagos University Teaching HospitalIdi Araba, Lagos
- Obafemi Awolowo University Teaching HospitalIle-Ife